Utilization of COVID-19 positive donors for Heart transplantation and associated short-term outcomes.
coronavirus-19
donor selection
heart transplantation
infection
rejection
survival
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
01
07
2022
revised:
04
11
2022
accepted:
04
12
2022
pmc-release:
01
05
2024
medline:
24
4
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
The safety and efficacy of using COVID-19 positive donors in heart transplantation (HT) are increasingly relevant, but not well established. The present study evaluated the characteristics and utilization of such donors and associated post-HT outcomes. All adult (≥18 years old) potential donors and HT recipients in the United States from April 21, 2020 to March 31, 2022 were included. Donor COVID-19 status was defined by the presence (or absence) of any positive test within 21 days of organ recovery. Donor and recipient characteristics and post-HT outcomes, including a primary composite of death, graft failure, and re-transplantation, were compared by donor COVID-19 status. Of 967 COVID-19(+) potential donors, 19.3% (n = 187) were used for HT compared to 26.7% (n = 6277) of COVID-19(-) donors (p < 0.001). Transplanted COVID-19(+) vs COVID-19(-) donors were younger, but otherwise were similar. Recipients of hearts from COVID-19+ vs COVID-19(-) donors less frequently received pre-HT inotropes (24.1% vs 31.7%, p = 0.023) and ventricular assist device therapy (29.7% vs 36.8%, p = 0.040). There were no significant differences in any post-HT outcome by donor COVID-19 status, including the primary composite outcome at 90 days (5.4% vs 5.6%, p = 0.91). Among COVID-19(+) donors, the presence of a subsequent negative test prior to transplant was not associated with posttransplant outcomes. Our results suggest that carefully selected COVID-19 positive donors may be used for HT with no difference in short-term post-transplant outcomes. Additional data regarding donor and recipient treatments and impact of vaccination should be collected to better inform our use of organs from COVID(+) donors.
Sections du résumé
BACKGROUND
The safety and efficacy of using COVID-19 positive donors in heart transplantation (HT) are increasingly relevant, but not well established. The present study evaluated the characteristics and utilization of such donors and associated post-HT outcomes.
METHODS
All adult (≥18 years old) potential donors and HT recipients in the United States from April 21, 2020 to March 31, 2022 were included. Donor COVID-19 status was defined by the presence (or absence) of any positive test within 21 days of organ recovery. Donor and recipient characteristics and post-HT outcomes, including a primary composite of death, graft failure, and re-transplantation, were compared by donor COVID-19 status.
RESULTS
Of 967 COVID-19(+) potential donors, 19.3% (n = 187) were used for HT compared to 26.7% (n = 6277) of COVID-19(-) donors (p < 0.001). Transplanted COVID-19(+) vs COVID-19(-) donors were younger, but otherwise were similar. Recipients of hearts from COVID-19+ vs COVID-19(-) donors less frequently received pre-HT inotropes (24.1% vs 31.7%, p = 0.023) and ventricular assist device therapy (29.7% vs 36.8%, p = 0.040). There were no significant differences in any post-HT outcome by donor COVID-19 status, including the primary composite outcome at 90 days (5.4% vs 5.6%, p = 0.91). Among COVID-19(+) donors, the presence of a subsequent negative test prior to transplant was not associated with posttransplant outcomes.
CONCLUSIONS
Our results suggest that carefully selected COVID-19 positive donors may be used for HT with no difference in short-term post-transplant outcomes. Additional data regarding donor and recipient treatments and impact of vaccination should be collected to better inform our use of organs from COVID(+) donors.
Identifiants
pubmed: 36609092
pii: S1053-2498(22)02250-1
doi: 10.1016/j.healun.2022.12.006
pmc: PMC10121733
mid: NIHMS1857004
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
651-659Subventions
Organisme : NHLBI NIH HHS
ID : F32 HL154750
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125303
Pays : United States
Informations de copyright
Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Heart Lung Transplant. 2022 Nov;41(11):1650-1653
pubmed: 36050205
Transplantation. 2022 Aug 1;106(8):e384-e385
pubmed: 35575769
Transplantation. 2022 Sep 1;106(9):e418-e419
pubmed: 35581692
J Card Fail. 2022 Jan;28(1):93-112
pubmed: 34481067
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Am J Transplant. 2021 Nov;21(11):3743-3749
pubmed: 34254424
Am J Transplant. 2022 Sep;22(9):2203-2216
pubmed: 35822320
J Heart Lung Transplant. 2022 Oct;41(10):1376-1381
pubmed: 35871114
J Card Fail. 2022 Dec;28(12):1727-1732
pubmed: 35718306
Transplant Direct. 2022 Jan 13;8(2):e1286
pubmed: 35047665
Am J Transplant. 2022 Sep;22(9):2217-2227
pubmed: 35730252